Evaxion A (EVAX) Long-Term Debt Repayments (2022)

Evaxion A (EVAX) reported Long-Term Debt Repayments of -$30000.0 for Q2 2022, little changed quarter-over-quarter from -$30000.0 in Q1 2022.

Evaxion A (EVAX) Long-Term Debt Repayments (2022) Analysis & Trends

Evaxion A has reported Long-Term Debt Repayments for 1 years, with the latest figure at -$30000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-21,671.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn	-

Download Data